Integra LifeSciences Announces Launch of the Integra(R) Allograft Wedge System for Extremity Reconstruction
February 08 2012 - 7:00AM
Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced
today the introduction of Integra® Allograft Wedge System, which
consists of simple pre-cut allograft wedges for both Evans and
Cotton osteotomies and a dedicated instrumentation set that is
designed to provide a method of assessing osteotomy space to aid in
the selection of the appropriate Integra® Allograft Wedge implant.
Osteotomies are procedures in which surgeons realign or remove a
segment of bone located near a damaged joint to help correct
deformities, typically in the foot. Integra® Allograft Wedge is
designed to provide bone grafting material for osteotomy
corrections. The Integra® Allograft Wedge is processed from human
cancellous bone, sterilized through the BioCleanse® Tissue
Sterilization Process and terminally sterilized using a validated
method to achieve a Sterility Assurance Level (SAL) of 10-6. The
wedge provides a natural scaffold for bone growth, as well as
biologic stability and structural support for deformity
corrections. It also eliminates significant harvest site
morbidity that may result from autograft removal. Integra will
feature the implant at the American Academy of Orthopaedic Surgeons
Annual Meeting, February 7-11, 2012 in San Francisco,
California.
"Integra® Allograft Wedge System offers four sizes (6, 8, 10 and
12mm), which gives surgeons a significant addition to their
treatment options and helps limit uncertainty by accommodating a
patient's unique surgical needs," said Bill Weber, Vice President
and General Manager, Integra Extremity Reconstruction.
The Integra® Allograft Wedge System is distributed through
Integra's Extremity Reconstruction sales organization, which
focuses on lower extremity fixation, upper extremity fixation,
tendon protection, peripheral nerve repair/protection and wound
repair.
Integra LifeSciences, a world leader in medical devices, is
dedicated to limiting uncertainty for surgeons, so they can
concentrate on providing the best patient care. Integra
offers innovative solutions in orthopedics, neurosurgery, spine,
reconstructive and general surgery. For more information, please
visit www.integralife.com.
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include, but are not limited to,
statements concerning the products and services provided by
Integra. Such forward looking statements involve risks and
uncertainties that could cause actual results to differ materially
from predicted or expected results. Among other things, the
willingness of surgical professionals to use Integra products may
affect the prospects for their use in surgical procedures. In
addition, the economic, competitive, governmental, technological
and other factors, identified under the heading "Risk Factors"
included in Item IA of Integra's Annual Report on Form 10-K for the
year ended December 31, 2010 and information contained in
subsequent filings with the Securities and Exchange Commission
could affect actual results.
BioCleanse is a registered trademark of RTI Biologics, Inc
CONTACT: Integra LifeSciences Holdings Corporation
Gianna Sabella
Director, Corporate Communications
(609) 936-2389
gianna.sabella@integralife.com
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From Aug 2024 to Sep 2024
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From Sep 2023 to Sep 2024